Boston Life Sciences Scores Breakthrough in Production of Anti-Angiogenic Troponin and Announces Addition of Director of Protein Development.

Business Editors and Health/Medical Writers

BIOWIRE2K

BOSTON--(BW HealthWire)--Jan. 4, 2001

Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that Dr. Irene Gonzalez has recently joined the Company as Director of Protein Development. Dr. Gonzalez joins the Company from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID). Dr. Gonzalez, who had previously given BLSI's anti-angiogenic program considerable support as a primary consultant, has developed a proprietary method for the purification of complex bacterial-produced recombinant proteins that conserves the biological activity of the native protein. This method should enable BLSI to produce large amounts of highly active Troponin at a relatively advantageous cost for the Company's upcoming clinical trials and, if approved, subsequent commercialization of this cancer therapeutic.

"Development of an economic, scale-up methodology for production of complex proteins while adhering to FDA mandated standards for purity and still retaining requisite biological activity has been a very difficult biotech industry problem. This has been especially true in the case of several anti-angiogenic agents. Dr. Gonzalez, in spearheading our internal proprietary approach, has enabled us to hurdle this problem," commented Dr. Marc Lanser, Chief Scientific Officer.

Prior to the NIAID, Dr. Gonzalez spent eleven years in the biotechnology industry in senior roles at Boston Biomedica and Biotrax. Dr. Gonzalez received her Ph.D. in Biological Sciences from Johns Hopkins University. During her career, she has developed an exceptional expertise in molecular biology, biochemistry, and bioinformatics, has received over twenty grants and fellowships, and has published approximately fifty abstracts, chapters, and full papers.

"We are delighted to welcome Irene to the management team at Boston Life Sciences," noted David Hillson, the Company's President and CEO. "Dr. Gonzalez is a recognized expert in protein development and will thus contribute critical momentum to the Company's drive to bring Troponin into clinical trials in 2001.

Troponin, BLSI's lead anti-metastatic cancer compound originally derived from the work of Professor Robert Langer while at Children's Hospital Boston, is an endogenous (naturally-occurring) anti-angiogenic protein that has been shown to inhibit lung metastases in animals at far lower doses than other anti-angiogenics in development. Extrapolation to the human equivalent should yield a convenient and very practical clinical dosing regimen of constant infusion of low dose Troponin, obviating the need for frequent hospital or clinic visits. The Company plans to file an IND for Troponin in the second quarter, and hopes to commence a Phase I/II clinical trial in the second half of this year.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane and Fluorotec, radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.